Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
Hyewon Lee, Igor Novitzky‐Basso, Dennis Dong Hwan Kim
Topics & Concepts
ImatinibMyeloid leukemiaMedicineDruggabilityTyrosine kinaseTyrosine-kinase inhibitorDasatinibHomoharringtonineOncologyHematologyPharmacologyAdverse effectChronic myelogenous leukemiaCancer researchLeukemiaCancerInternal medicineBiologyReceptorBiochemistryGeneChronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesChronic Lymphocytic Leukemia Research